Sign In
Buy OST
$1.70
+0 (+0%)
At Close: Jun 03, 2026
Bronstein, Gewirtz & Grossman LLC Urges Ostin Technology Group Co., Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Wednesday, 18'th Feb 2026
New class action for Ostin (OST) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of Apr. 17, 2026.
Stockholder Alert: Robbins LLP Informs Investors of the Ostin Technology Group Co., Ltd. Class Action
06:00am, Tuesday, 17'th Feb 2026
SAN DIEGO--(BUSINESS WIRE)---- $OST #OstinTechnologyGroupCoLtd--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Ostin Tech
San Diego, California--(Newsfile Corp. - February 16, 2026) - The law firm of Morris Kandinov LLP announces that purchasers or acquirers of common stock of Ostin Technology Group Co., Ltd., Ltd. (NASD
Request for FDA Rolling Review submitted to FDA on January 30, 2026 Non-Clinical and CMC BLA modules submitted to FDA At FDA's request, Type D Meeting expected in March 2026 to review Comparative Onco
Activation of immune blood biomarkers from interferon gamma pathway distinguished long term survivors (>=2 years) from short-term survivors (=2 years) from short-term survivors (
OS Therapies Provides First Half 2026 Corporate Outlook
07:40am, Monday, 05'th Jan 2026
Company finalizing preparations for end of January 2026 U.S. FDA Biologics License Application (BLA) submission for OST-HER2 program in the prevention or delay of recurrent, fully resected, pulmonary
FDA confirmed that data from single-arm studies in rare diseases, such as in ultra-rare deadly pediatric cancer osteosarcoma, could support a Biologics Licensing Application (BLA) under Accelerated Ap
Alignment achieved on all key points surrounding non-clinical, CMC and post-market authorization confirmatory study design Biomarker data advanced as key pre-specified surrogate clinical efficacy endp
OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility
08:01am, Friday, 05'th Dec 2025
U.S. FDA grants waiver of application fee for BLA Filing of OST-HER2 Scheduled pre-Marketing Authorisation Application meeting with United Kingdom's Medicines and Healthcare products Regulatory Agency
OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization
09:21am, Tuesday, 25'th Nov 2025
New York, New York--(Newsfile Corp. - November 25, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today a
Comparing Ostin Technology Group (NASDAQ:OST) and Ultralife (NASDAQ:ULBI)
03:09am, Friday, 14'th Nov 2025
Ostin Technology Group (NASDAQ: OST - Get Free Report) and Ultralife (NASDAQ: ULBI - Get Free Report) are both small-cap computer and technology companies, but which is the better investment? We will
New York, New York--(Newsfile Corp. - October 22, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate b
75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001) 100% of patients who achieved 12 month event free survival achieved 2 y
OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update
07:40am, Tuesday, 30'th Sep 2025
Company updates sequence of OST-HER2 regulatory submissions, prioritizing UK MHRA conditional Marketing Authorisation Application (MAA) submission following positive August 2025 Scientific Advice Meet
Clinical data from Phase 1b prostate cancer trial to be released in Q4/25 Additionally, updated 2-year overall survival data from all 40 patients in the Phase 2b clinical trial of OST-HER2 in the prev
